The challenging funding environment will likely prompt small- and mid-cap listed life sciences companies to seek financing through private investments in public equity. Small- and mid-cap life sciences companies typically draw upon two major fundraising sources: licensing and collaboration agreements (which have the potential to provide funding without dilution) and equity injections. While equity injections can involve contributions-in-kind from strategic partners, they more commonly take the form of private investments in public equity (pipes) by financial or strategic partners. Please see full Alert below for more information.
Source: 5 Tips for Navigating PIPEs in the European Life Sciences Sector